Verona Pharma plc
VRNA
Rang în acțiuni
#2228
Verona Pharma plc is a biopharmaceutical company currently in its clinical... Verona Pharma plc is a biopharmaceutical company currently in its clinical development phase, focusing on the research, development, and eventual market launch of new therapies for respiratory illnesses where current treatments are inadequate. Its primary experimental medication is ensifentrine, an inhaled compound designed to simultaneously block both phosphodiesterase (PDE) 3 and PDE4 enzymes. This unique mechanism allows it to function both as a bronchodilator, helping to open the airways, and as an anti-inflammatory agent within a single drug. Ensifentrine is presently undergoing advanced (Phase 3) clinical trials to evaluate its effectiveness in treating chronic obstructive pulmonary disease (COPD), asthma, and cystic fibrosis. To provide versatile administration options, the company is developing ensifentrine in three distinct formulations: a nebulizer solution, a dry powder inhaler (DPI), and a pressurized metered-dose inhaler (pMDI). Verona Pharma plc was established in 2005 and conducts its operations from its headquarters in London, United Kingdom.
Preț acțiune
$106.91
Ultima sincronizare: 2025-10-07
Capitalizare de piață
$9.09B
Schimbare (1 zi)
0.00%
Schimbare (1 an)
0.00%
Țară
GB
Tranzacționează Verona Pharma plc (VRNA)
Categorie
Healthcare
Câștiguri pentru Verona Pharma plc (VRNA)
Câștiguri în Jun 2025 TTM: $-56.52M
Conform celor mai recente rapoarte financiare ale Verona Pharma plc, câștigurile actuale ale companiei sunt $-56.52M. În anul 2023, compania a înregistrat un câștig de $-42.28M, o creștere față de câștigului din 2022, care a fost de $-56.62M. Câștigurile afișate pe această pagină sunt cele înainte de dobânzi și impozite, cunoscute și ca EBIT.
Istoricul câștigurilor pentru Verona Pharma plc din 2005 până în 2026
Câștiguri la sfârșitul fiecărui an
| An | Câștiguri | Schimbă |
|---|---|---|
| 2026 (TTM) | $-56.52M | -56.62% |
| 2024 | $-130.30M | 208.20% |
| 2023 | $-42.28M | -25.33% |
| 2022 | $-56.62M | 37.75% |
| 2021 | $-41.10M | -13.52% |
| 2020 | $-47.53M | 17.27% |
| 2019 | $-40.53M | 31.86% |
| 2018 | $-30.74M | -9.75% |
| 2017 | $-34.06M | 362.02% |
| 2016 | $-7.37M | -44.44% |
| 2015 | $-13.27M | 126.33% |
| 2014 | $-5.86M | 25.78% |
| 2013 | $-4.66M | 75.08% |
| 2012 | $-2.66M | -40.09% |
| 2011 | $-4.44M | -2.04% |
| 2010 | $-4.54M | 8.38% |
| 2009 | $-4.18M | 45.74% |
| 2008 | $-2.87M | -40.29% |
| 2007 | $-4.81M | 105.89% |
| 2006 | $-2.34M | -3,133.92% |
| 2005 | $76.99K | 0.00% |
Câștiguri pentru companii similare sau concurente
| Companie | Câștiguri | Diferență de câștiguri | Țara |
|---|---|---|---|
| $5.27B | -9,432.91% |
US
|
|
| $-3.09B | 5,361.85% |
US
|
|
| $-4.02B | 7,005.88% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -3,551.30% |
NL
|
